Prolactin-raising antipsychotics may increase gynecological cancer risk
Women prescribed antipsychotics that raise the levels of prolactin, a hormone that stimulates milk production and regulates reproductive hormones, had double the rate of…
Gynecological cancer
Stenoparib may improve survival in hard-to-treat ovarian cancer: Data
The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
Elahere approved in Canada for hard-to-treat ovarian cancer
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is now approved in Canada for adults with platinum-based, chemotherapy-resistant, ovarian, fallopian tube, or primary peritoneal cancer…
New drug for endometrial cancer wins FDA’s breakthrough status
The U.S. Food and Drug Administration (FDA) has awarded breakthrough therapy status to rinatabart sesutecan (Rina-S), an investigational treatment for certain cancers, including advanced endometrial…
Groups unite to raise gynecologic cancer awareness in September
September is Gynecologic Cancer Awareness Month, and advocacy organizations are hosting events, sharing information on social media, and raising funds to advance research.
Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
